1. No category

Sunday, October 19, 2014 Industry Sponsored Sessions : UEG Week Final Programme
Industry Sponsored
Sessions
345
UEG Week Final Programme : Industry Sponsored Sessions
Sunday, October 19, 2014
Industry Sponsored Sessions
Sunday, October 19, 2014
Industry Sponsored Session
16:15 – 17:45
Hall B
When reflux symptoms persist despite PPI:
What should we do?
Industry Sponsored Session
16:15 – 17:45
Hall F2
Management of Colonic Diverticular
Disease: Where is the evidence?
(RB)
(ALFA WASSERMANN S.p.A.)
Chair: Heinz Hammer, Austria
Chair: Carmelo Scarpignato, Italy
Welcome and introductions
Heinz Hammer, Austria
Introductory remarks
Carmelo Scarpignato, Italy
Prevalence and burden of the problem
Hashem El-Serag, USA
Clinical picture and natural history
Robin Spiller, United Kingdom
Causes of these symptoms
Daniel Sifrim, United Kingdom
Symptomatology in IBS and DD: Is gut
microbiota the missing link?
Giovanni Barbara, Italy
Assessing the patients
Frank Zerbib, France
Therapeutic advances
Peter Bytzer, Denmark
Question and answer session
Industry Sponsored Session
16:15 – 17:45
Hall F1
Evolution in opioid-induced constipation
management
(AstraZeneca)
Chair: Andrew Davies, United Kingdom
Chair’s introduction
Andrew Davies, United Kingdom
Symptoms of opioid-induced constipation:
is it more than reduced bowel movements?
AsbjØrn Drewes, Denmark
What are the burdens of opioid-induced
constipation for the patient and healthcare
professionals?
Andrew Davies, United Kingdom
Novel strategies for the treatment of
opioid-induced constipation
Jan Tack, Belgium
Questions and answers
Close
Andrew Davies, United Kingdom
346
Therapeutic options for Diverticular Disease
Fermin Mearin, Spain
Conclusion
Carmelo Scarpignato, Italy
Industry Sponsored Session
18:00 – 19:30
Hall L/M
Acid-related disorders: Myths and realities
on formulations and PPI safety
(Takeda Pharmaceuticals International)
Chair: Colin Howden, USA
Welcome and introductions
Colin Howden, USA
Benefits of orally dissolving PPI
Richard Hunt, Canada
Treating gastric acid related disorders
with IV PPI
David Metz, USA
Update on drug-drug interactions
Colin Howden, USA
Q & A – Panel discussion
Sunday, October 19, 2014 Industry Sponsored Sessions : UEG Week Final Programme
Industry Sponsored Session
18:00 – 19:30
Hall N
Revestive (teduglutide): A new treatment
for short bowel syndrome
Industry Sponsored Session
18:00 – 19:30
Hall B
Optimizing care in Ulcerative Colitis – How
can we raise the bar in 2015?
(NPS Pharma International Limited)
(AbbVie Inc.)
Chair: Simon Gabe, United Kingdom
Chair: Walter Reinisch, Austria
Introduction
Simon Gabe, United Kingdom
Introduction
Walter Reinisch, Austria
Short bowel syndrome – A rare but
complex condition
Simon Gabe, United Kingdom
The burden of ulcerative colitis –
A progressive disease?
Jean-Frédéric Colombel, USA
Introducing teduglutide: MoA and clinical
trial results
Palle Jeppesen, Denmark
Biologic therapy in ulcerative colitis –
When to use and how to optimize?
Shomron Ben-Horin, Israel
Identifying suitable patients for teduglutide
Simon Gabe, United Kingdom
The evolution of clinical trials in ulcerative
colitis
Subrata Ghosh, Canada
Starting patients on teduglutide, initial and
medium term management
Ulrich-Frank Pape, Germany
Q & A and summary
Walter Reinisch, Austria
Real world experience: A longer term
perspective
Kishore Iyer, USA
Q & A
347
UEG Week Final Programme : Industry Sponsored Sessions
Monday, October 20, 2014
Industry Sponsored Sessions
Monday, October 20, 2014
Industry Sponsored Session
07:00 – 08:00
Hall F1
The new era of biologic therapy in
gastroenterology
Industry Sponsored Session
18:00 – 19:30
Hall B
Improving quality of care in IBD: Ideas
worth sharing
(Celltrion Healthcare)
(AbbVie Inc.)
Chairs:Walter Reinisch, Austria
Clemens Dejaco, Austria
Welcome and introduction
Simon Travis, United Kingdom
Welcome & Introduction
Walter Reinisch, Austria
Clemens Dejaco, Austria
What doctors can learn from each other
Stefan Larsson, Sweden
Improvement of hospital-based care - 2014
report from KPMG
Hilary Thomas, United Kingdom
Gert van Assche, Belgium
‘Gold-Standard’ anti-TNF antibody
therapy in IBD, Infliximab
Walter Reinisch, Austria
Case Presentation Part I
Dong-Il Park, Republic of Korea
Case Presentation Part II
Jørgen Jahnsen, Norway
Tailoring IBD care: Is there a recipe for
success?
Brian Feagan, Canada
Remo Panaccione, Canada
Q & A
Discussion
Summary & Close
Walter Reinisch, Austria
Clemens Dejaco, Austria
Summary and close
Simon Travis, United Kingdom
Industry Sponsored Session
18:00 – 19:30
New horizons in IBD therapy
Hall D
(Takeda)
Industry Sponsored Session
18:00 – 19:30
Hall C
To treat. To cure. Sharing the journey
to eradicate HCV
(AbbVie Inc.)
Chair: Herbert Tilg, Austria
Chair: Markus Peck-Radosavljevic, Austria
Chairman’s introduction: Opportunities
for clinical success
Herbert Tilg, Austria
Samuel S. Lee, Canada
Massimo Puoti, Italy
Therapeutic approaches in IBD and
treatment goals
Stefan Schreiber, Germany
New treatment options in IBD; today
and the future
Silvio Danese, Italy
Panel discussion: Treatment decisionmaking in clinical practice
Geert d’Haens, The Netherlands
Questions and answers
348
Monday, October 20, 2014 Industry Sponsored Sessions : UEG Week Final Programme
Industry Sponsored Session
18:00 – 19:30
Hall F1
Prokinetics in chronic constipation: The
journey from clinical research to daily
practice
(Shire)
Welcome and introductions
Jan Tack, Belgium
Prucalopride: Shaping the current treatment landscape in chronic constipation
Jan Tack, Belgium
The gastroenterologist’s case file:
Challenges in chronic constipation
diagnosis and treatment
Yan Yiannakou, United Kingdom
Prucalopride: What is beyond the horizon?
Hubert Piessevaux, Belgium
Q & A and panel discussion
Jan Tack, Belgium
Closing remarks
Jan Tack, Belgium
Industry Sponsored Session
18:00 – 19:30
Hall I/K
Is blue-light laser imaging “Darwinism”
in endoscopy?
(Fujifilm Europe GmbH)
Chairs:Horst Neuhaus, Germany
Thierry Ponchon, France
Paul Fockens, The Netherlands
Thierry Ponchon, France
Jacques Bergman, The Netherlands
Mitsuhiro Fujishiro, Japan
Yutaka Saito, Japan
349
UEG Week Final Programme : Industry Sponsored Sessions
Tuesday, October 21, 2014
Industry Sponsored Sessions
Tuesday, October 21, 2014
Industry Sponsored Session
07:00 – 08:00
Hall F1
Moving forward – New PPIs for today’s
patients
Industry Sponsored Session
18:00 – 19:30
Hall B
Achieving long-term success: Continuous
control of Ulcerative Colitis
(Takeda)
(MSD)
Challenges facing today’s PPI patients
Peter Malfertheiner, Germany
Next steps in PPI development – Targeting
the patients’ needs
David C. Metz, USA
Symptom relief – Today’s patients’ priority
Joaquim P. Moraes-Filho, Brazil
Industry Sponsored Session
18:00 – 19:30
Hall E
Wheat bran fibre: And it’s role in gut
health
(Kellogg’s)
Chair: Angie Jefferson, United Kingdom
Dietary Fibre: What is it, how does it act
and what forms are best for digestive
health
Kathryn O’Sullivan, Ireland
Intact cereal dietary fibre and digestive
health: A critical assessment of its role in
the prevention and management of gut
symptoms and disorders
Jan de Vries, The Netherlands
Digestive function during the menstrual
cycle: Is there an association with fibre
consumption?
Louise Dye, United Kingdom
The economics of constipation: A European
review
Kathryn O’Sullivan, Ireland
Chair: Geert d’Haens, Belgium
Welcome and opening remarks
Geert d’Haens, Belgium
From clinical trials to clinical practice: What
are the unmet needs in the management
of UC?
Geert d’Haens, Belgium
Achieving continuous disease control: What
are the treatment options for UC?
Walter Reinisch, Austria
Leveraging our knowledge of UC: How can
we best use our experience when selecting
a treatment?
Alessandro Armuzzi, Italy
Panel discussion / Q & A
Industry Sponsored Session
18:00 – 19:30
Hall F1
Cognitive impairment in liver cirrhosis: The
differential diagnosis
(Norgine)
Chair: Sara Montagnese, Italy
Welcome and objectives
Sara Montagnese, Italy
Liver cirrhosis: Patient’s voice
Patient video
HE practise guidelines: What do they mean
for clinical practise
Joost P.H. Drenth, The Netherlands
THE EPHE STUDY: Epidemiology and
diagnosis of hepatic encephalopathy
Joachim Labenz, Germany
Liver cirrhosis: Specialist care / differential
diagnosis
Sara Montagnese, Italy
350
Q/A and conclusions
Tuesday, October 21, 2014 Industry Sponsored Sessions : UEG Week Final Programme
Industry Sponsored Session
18:00 – 19:30
Hall G/H
New insights into the clinical and economic
impact of Saccharomyces boulardii in
antibiotic-associated diarrhea
(BIOCODEX)
Chair: Philippe Marteau, France
Introduction
Awareness of probiotics: Survey of 10
countries
Christian Boggio-Marzet, Argentina
Saccharomyces boulardii impact on gut
microbiota, antibiotic-associated diarrhea,
and Clostridium difficile disease
Ciaran Kelly, USA
Effectiveness of Saccharomyces boulardii in
reducing hospitalization costs related to
antibiotic-associated diarrhea
Sebastian Vermeersch, Belgium
Q & A session
Conclusion
UEG thanks its longterm partners
for their continuous support
351